¼ÓÄôóÎÀÉú²¿½ÓÊÜÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÐÂÒ©LecanemabµÄÉêÇë

5ÔÂ16ÈÕ£¬¼ÓÄôóÎÀÉú²¿ÒѾ­½ÓÊÜÁËLecanemabµÄÐÂÒ©ÉêÇ루NDS£©¡£ LecanemabÊÇÒ»ÖÖʵÑéÐÔ¿¹µí·ÛÑùÂѰצ£¨A¦Â£©Ô­ÏËά*¿¹Ì壬ÓÃÓÚÖÎÁƾßÓÐÄÔ²¿µí·ÛÑùÂѰײ¡ÀíµÄÔçÆÚ°¢¶û´Äº£Ä¬²¡£¨AD£©¡ª¡ª°üÂÞÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°­ºÍÇá¶ÈAD¡£

±¾´ÎNDSÊÇ»ùÓÚIIIÆÚClarity ADÑо¿ºÍIIbÆÚÁÙ´²Ñо¿£¨Study 201£©µÄ½á¹û£¬ÕâЩÑо¿±íÃ÷£¬LecanemabµÄÖÎÁÆÏÔʾÁËÔçÆÚADÁÙ´²Ë¥Í˵ļõÉÙ¡£LecanemabÄÜÑ¡ÔñÐԵؽáºÏ²¢Ïû³ý¿ÉÈÜÇÒÓж¾µÄA¦Â¾Û¼¯ÎԭÏËά£©£¬ÕâЩ¾Û¼¯Îï±»ÈÏΪÊǵ¼ÖÂADÉñ¾­¶¾ÐÔµÄÔ­Òò¡£Òò´Ë£¬Lecanemab¾ßÓжԼ²²¡²¡Àí·¢ÉúÓ°Ïì²¢¼õ»º¼²²¡½øÕ¹µÄDZÁ¦¡£LecanemabµÄClarity ADÑо¿µ½´ïÁËÖ÷ÒªÖÕµãºÍËùÓÐÒªº¦´ÎÒªÖյ㣬½á¹û¾ßÓи߶Èͳ¼ÆѧÒâÒå¡£2022Äê11Ô£¬Clarity ADÑо¿µÄ½á¹ûÔÚ2022Äê°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑ飨CTAD£©»áÒéÉÏÐû²¼£¬²¢Í¬Ê±·¢±íÓÚͬÐÐÆÀÒéµÄҽѧÔÓÖ¾¡¶ÐÂÓ¢¸ñÀ¼Ò½Ñ§ÔÓÖ¾¡·¡£

LecanemabÔÚÃÀ¹úµÄÉóÆÀ½ø³Ì

LecanemabÒÑÔÚ¿ìËÙͨµÀÈ϶¨Ï»ñµÃÃÀ¹úFDAÅú×¼£¬²¢ÓÚ2023Äê1ÔÂ18ÈÕÉÏÊС£¸ÃÅú×¼ÊÇ»ùÓÚLecanemabµÄIIÆÚÊý¾Ý£¬¸ÃÊý¾Ý±íÃ÷LecanemabÄܼõÉÙ´óÄÔÖÐA¦Â°ß¿éµÄ»ýÀÛ¡ª¡ªADµÄÒ»¸ö¾ö¶¨ÐÔÌØÕ÷£¬ºóÐøÅú×¼½«È¡¾öÓÚLecanemabÔÚÑéÖ¤ÐÔÊÔÑéÖеÄÁÙ´²»ñÒæ¡£

2023Äê1ÔÂ6ÈÕ£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÏòÃÀ¹úFDAÌá½»ÁËÒ»·ÝÔö²¹ÉúÎïÖƼÁÐí¿ÉÉêÇ루sBLA£©£¬ÒÔ»ñµÃ´«Í³Í¾¾¶µÄÅú×¼¡£3ÔÂ3ÈÕ£¬FDAƾ¾ÝClarity ADµÄÁÙ´²Êý¾Ý½ÓÊÜÁËÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾µÄsBLA£¬¶øÇÒÊÚÓèÁËLecanemabÓÅÏÈÉóÆÀ£¬´¦·½Ò©Óû§ÊÕ·Ñ·¨°¸£¨PDUFA£©µÄÉúЧÈÕÆÚΪ2023Äê7ÔÂ6ÈÕ¡£FDA¼Æ»®ÓÚ6ÔÂ9ÈÕÕÙ¿ª×ÉѯίԱ»áÌÖÂÛ¸ÃÉêÇë¡£

LecanemabÔÚÈÕ±¾µÄÉóÆÀ½ø³Ì

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÓÚ2023Äê1ÔÂ16ÈÕÏòÈÕ±¾Ò©Æ·ºÍÒ½ÁÆÆ÷е¹ÜÀí¾Ö£¨PMDA£©Ìá½»ÁËÉú²úºÍÏúÊÛÅú×¼ÉêÇë¡£ÈÕ±¾ºñÉúÀͶ¯Ê¡ÒÑÓÚ1ÔÂ26ÈÕÅú×¼LecanemabµÄÓÅÏÈÉó²é¡£±¾´ÎÉóÆÀ£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÀûÓÃÁËPMDAµÄÊÂÏÈÆÀ¹À×Éѯϵͳ£¬ÒÔËõ¶ÌLecanemabµÄÉó²éÖÜÆÚ¡£

LecanemabÔÚÅ·ÖÞºÍÖйúµÄÉóÆÀ½ø³Ì

2023Äê1ÔÂ9ÈÕÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÏòÅ·ÖÞÒ©Æ·¹ÜÀí¾Ö£¨EMA£©Ìá½»ÁËÉÏÊÐÐí¿ÉÉêÇ루MAA£©£¬¸ÃÉêÇëÓÚ1ÔÂ26ÈÕ±»ÊÜÀí¡£À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÓÚ2022Äê12ÔÂÏòÖйú¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾Ö£¨NMPA£©Ìá½»ÁËBLAµÄÊý¾Ý£¬²¢ÓÚ2ÔÂ27ÈÕ»ñµÃÓÅÏÈÉóÆÀ×ʸñ¡£

LecanemabµÄÈ«Çò¿ª·¢ºÍ¼à¹ÜÌá½»ÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ö÷µ¼£¬¶ø²úÎïÔòÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍƹã¡£ÆäÖУ¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÓµÓÐ×îÖÕ¾ö²ßȨ¡£

*Ô­ÏËά£º75- 5000kdµÄ´ó¦Â¾Û¼¯¿ÉÈÜÖÖ1

1 S?derberg, L., Johannesson, M., Nygren, P. et al. Lecanemab, Aducanumab, and Gantenerumab – Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer¡¯s Disease. Neurotherapeutics (2022). https://doi.org/10.1007/s13311-022-01308-6. Accessed February 9, 2023